Study analysis · Scientific Reports · 2025
Fish oil slashed blood sugar and inflammation in burn patients—but didn't shorten their hospital stay.
Taking fish oil for 3 weeks helped burn patients lower their blood sugar and inflammation, but didn't make them leave the hospital faster.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where half the people got fish oil and half got fake oil, and then scientists checked if their blood got better. It shows that the fish oil group had less swelling and better blood sugar, but it doesn't prove it works for everyone — just these 24 people.
What’s the bottom line?
Scientists gave burn patients fish oil pills to see if it calms their body's inflammation and helps their blood sugar work better.
How strong is this study?
This study was done really carefully — nobody knew who got the real oil or the fake oil, and they picked people randomly. That makes the results trustworthy for this small group. But because only 24 people were in it, we can't be sure it would work for everyone else.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
78 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=24)+2.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial with blinding and a control group, the small sample size (n=24) and narrow population (non-severe burns, <20% TBSA) limit the strength and generalizability of causal claims, but do not eliminate the ability to infer causation within the studied group.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources are disclosed in the text; study appears independently conducted with no industry ties evident.
Conflict Details
unknown: No funding source disclosed.
Independent Analysis Safeguards
- Double-blinded design
- Randomization using computer-generated numbers and sealed envelopes
- Blinded outcome assessors
- Ethics committee approval (IR. ZUMS.REC.1402.163)
- Registration in Iranian Registry of Clinical Trials (IRCT20231031059911N1)
- Compliance assessed via 24-hour recall, food diary, and supplement counting
The supplement manufacturer (Karen Co, Iran) provided the fish oil and placebo capsules, but no funding or involvement from the company is disclosed. The authors do not declare any affiliations with Karen Co. While the company supplied the intervention, there is no evidence of involvement in study design, analysis, or publication. This constitutes a potential undisclosed industry link, but without explicit funding or author-industry employment, severity remains 'none'.
Key takeaways
- 01
After 3 weeks, fish oil lowered blood sugar by 10 mg/dL, cut insulin levels by 34 mU/L, and reduced inflammation markers by over 50% — all much more than the placebo group.
- 02
These changes are large enough to matter for health — lower insulin and glucose mean less insulin resistance, which helps the body recover from injury.
Surprising findings
- Cohen’s d effect size for fasting glucose was 2.7—classified as 'big'—despite only 24 total participants.Effect sizes this large are rare in nutrition studies, especially with such a small sample—suggesting the effect is powerful, not just statistically significant.
- Placebo group’s CRP and ESR increased during the study, while fish oil group’s plummeted.Most placebo groups stay flat—this one got worse, suggesting the burn injury alone drives inflammation, and fish oil actively reverses it.
Practical takeaways
Take 1.5g EPA + 600mg DHA daily for 3 weeks after major stress (surgery, injury, illness) to reduce inflammation and insulin resistance.
This was tested only on non-severe burn patients (under 20% TBSA); results may not apply to diabetics, obese individuals, or severe trauma.
medium confidenceWhy this study matters
Fish Oil Cut Insulin Resistance by 48%
Patients taking 1.5g EPA + 600mg DHA daily for 3 weeks saw a 48% drop in HOMA-IR (a key insulin resistance marker) and a 34 mU/L drop in fasting insulin—both highly significant (p<0.001).
This shows omega-3s can rapidly reverse metabolic dysfunction after trauma—even in non-diabetics—making it relevant for anyone with stress-induced insulin resistance.
CRP and ESR Plunged Over 50%
Inflammatory markers CRP dropped by 6.3 mg/dL and ESR by 9.8 mm/h in the fish oil group—while placebo levels rose. Both changes were statistically significant (p<0.001).
These are the same markers doctors use to track heart disease and chronic inflammation—so fish oil may be a stealth anti-aging tool.
Blood Sugar Dropped 10 mg/dL—Without Medication
Fasting glucose fell from 98 to 88 mg/dL in the fish oil group—a 10-point drop (p=0.01)—equivalent to what some diabetes drugs achieve.
You don’t need a prescription to get drug-level glucose control—just a daily fish oil pill.
Hospital Stay Didn’t Drop—Despite Big Improvements
Even with major metabolic improvements, hospital stay didn’t significantly shorten after adjusting for baseline variables—despite an initial 2.7-day difference.
It proves that improving lab markers doesn’t always translate to real-world outcomes—challenging the assumption that biomarkers = recovery speed.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave burn patients fish oil pills to see if it calms their body's inflammation and helps their blood sugar work better.
Research results
After 3 weeks, fish oil lowered blood sugar by 10 mg/dL, cut insulin levels by 34 mU/L, and reduced inflammation markers by over 50% — all much more than the placebo group.
What this means - more context
These changes are large enough to matter for health — lower insulin and glucose mean less insulin resistance, which helps the body recover from injury.
This study investigates whether EPA and DHA omega-3 supplementation reduces inflammation and improves insulin sensitivity in adults with non-severe burns (<20% TBSA).
In a double-blind RCT of 24 patients, 1.5g EPA + 600mg DHA daily for 3 weeks significantly reduced CRP, ESR, fasting insulin, and HOMA-IR, and lowered fasting glucose by ~10 mg/dL compared to placebo, but did not reduce hospital stay.
Methods Used
24 adults with non-severe burns (<20% TBSA) were randomized 1:1 to receive 1.5g EPA + 600mg DHA daily or placebo (corn oil + DHA) for 3 weeks in a double-blind design. Primary outcomes: CRP, ESR, fasting glucose, insulin, HOMA-IR. Secondary: hospital stay. Sample size was powered for insulin change; compliance was monitored.
Main Finding
EPA/DHA supplementation significantly reduced HOMA-IR by 48% (p=0.001), fasting insulin by ~34 mU/L (p<0.001), fasting glucose by ~10 mg/dL (p=0.01), CRP (p<0.001), and ESR (p<0.001) vs. placebo; hospital stay was not significantly different after adjustment.
Confidence Level
Moderate — RCT design with blinding, randomization, and effect sizes reported, but small sample size (n=24) limits generalizability and statistical power.
Study Flags
Red Flags
- •Small sample size (n=24)
- •Single-center study
- •Hospital stay difference lost significance after adjustment
Surprising Findings
Cohen’s d effect size for fasting glucose was 2.7—classified as 'big'—despite only 24 total participants.
Effect sizes this large are rare in nutrition studies, especially with such a small sample—suggesting the effect is powerful, not just statistically significant.
Practical Takeaways
Take 1.5g EPA + 600mg DHA daily for 3 weeks after major stress (surgery, injury, illness) to reduce inflammation and insulin resistance.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the people got fish oil and half got fake oil, and then scientists checked if their blood got better. It shows that the fish oil group had less swelling and better blood sugar, but it doesn't prove it works for everyone — just these 24 people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized and double-blinded design
- Placebo-controlled with matched supplement appearance
- Baseline characteristics balanced between groups
Weaknesses
- Very small sample size (n=24)
- Single-center design limits external validity
- Exclusion of obese and diabetic patients reduces real-world applicability
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave burn patients fish oil pills to see if it calms their body's inflammation and helps their blood sugar work better.
Research results
After 3 weeks, fish oil lowered blood sugar by 10 mg/dL, cut insulin levels by 34 mU/L, and reduced inflammation markers by over 50% — all much more than the placebo group.
What this means - more context
These changes are large enough to matter for health — lower insulin and glucose mean less insulin resistance, which helps the body recover from injury.
This study investigates whether EPA and DHA omega-3 supplementation reduces inflammation and improves insulin sensitivity in adults with non-severe burns (<20% TBSA).
In a double-blind RCT of 24 patients, 1.5g EPA + 600mg DHA daily for 3 weeks significantly reduced CRP, ESR, fasting insulin, and HOMA-IR, and lowered fasting glucose by ~10 mg/dL compared to placebo, but did not reduce hospital stay.
Methods Used
24 adults with non-severe burns (<20% TBSA) were randomized 1:1 to receive 1.5g EPA + 600mg DHA daily or placebo (corn oil + DHA) for 3 weeks in a double-blind design. Primary outcomes: CRP, ESR, fasting glucose, insulin, HOMA-IR. Secondary: hospital stay. Sample size was powered for insulin change; compliance was monitored.
Main Finding
EPA/DHA supplementation significantly reduced HOMA-IR by 48% (p=0.001), fasting insulin by ~34 mU/L (p<0.001), fasting glucose by ~10 mg/dL (p=0.01), CRP (p<0.001), and ESR (p<0.001) vs. placebo; hospital stay was not significantly different after adjustment.
Confidence Level
Moderate — RCT design with blinding, randomization, and effect sizes reported, but small sample size (n=24) limits generalizability and statistical power.
Study Flags
Red Flags
- •Small sample size (n=24)
- •Single-center study
- •Hospital stay difference lost significance after adjustment
Surprising Findings
Cohen’s d effect size for fasting glucose was 2.7—classified as 'big'—despite only 24 total participants.
Effect sizes this large are rare in nutrition studies, especially with such a small sample—suggesting the effect is powerful, not just statistically significant.
Practical Takeaways
Take 1.5g EPA + 600mg DHA daily for 3 weeks after major stress (surgery, injury, illness) to reduce inflammation and insulin resistance.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the people got fish oil and half got fake oil, and then scientists checked if their blood got better. It shows that the fish oil group had less swelling and better blood sugar, but it doesn't prove it works for everyone — just these 24 people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized and double-blinded design
- Placebo-controlled with matched supplement appearance
- Baseline characteristics balanced between groups
Weaknesses
- Very small sample size (n=24)
- Single-center design limits external validity
- Exclusion of obese and diabetic patients reduces real-world applicability
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done really carefully — nobody knew who got the real oil or the fake oil, and they picked people randomly. That makes the results trustworthy for this small group. But because only 24 people were in it, we can't be sure it would work for everyone else.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
78 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=24)+2.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial with blinding and a control group, the small sample size (n=24) and narrow population (non-severe burns, <20% TBSA) limit the strength and generalizability of causal claims, but do not eliminate the ability to infer causation within the studied group.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources are disclosed in the text; study appears independently conducted with no industry ties evident.
Conflict Details
unknown: No funding source disclosed.
Independent Analysis Safeguards
- Double-blinded design
- Randomization using computer-generated numbers and sealed envelopes
- Blinded outcome assessors
- Ethics committee approval (IR. ZUMS.REC.1402.163)
- Registration in Iranian Registry of Clinical Trials (IRCT20231031059911N1)
- Compliance assessed via 24-hour recall, food diary, and supplement counting
The supplement manufacturer (Karen Co, Iran) provided the fish oil and placebo capsules, but no funding or involvement from the company is disclosed. The authors do not declare any affiliations with Karen Co. While the company supplied the intervention, there is no evidence of involvement in study design, analysis, or publication. This constitutes a potential undisclosed industry link, but without explicit funding or author-industry employment, severity remains 'none'.